Sanofi-Aventis Merger Clears FTC; Estorra Rights To Be Divested
Executive Summary
Sanofi and Aventis will begin integrating management and operations following the Federal Trade Commission's July 28 approval of the merger of the two companies
You may also be interested in...
Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity
The House Energy and Commerce Committee's inquiries into Sanofi-Aventis' Ketek could be a jumping-off point for a wide-ranging congressional look into the integrity of clinical trials and oversight of companies involved in those trials
Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity
The House Energy and Commerce Committee's inquiries into Sanofi-Aventis' Ketek could be a jumping-off point for a wide-ranging congressional look into the integrity of clinical trials and oversight of companies involved in those trials
Sanofi-Aventis board vacancy
Aventis business development head and board member Thomas Hoefstatter announces plans to resign. He was expected to serve on the 18-member management committee of the newly merged company's board, and would have been one of 10 representatives of Aventis. Sanofi-Aventis says it is too soon to know how it will proceed with the management and board vacancy, but that it will meet its deadline for putting the new operational structure in place by Jan. 1 (1"The Pink Sheet" Aug. 2, 2004, p. 3)...